AGENT III研究
Ad5FGF-4 gene
Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4)
Primary Endpoint:
Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year.
Secondary Endpoints:
Time to number of patients with coronary events and death at 12 months
Time to ST depression, angina, and quality of life parameters
AGENT III: 12 week results
Presented at TCT 2004
Placebo
Low-dose
High-dose
415 patients with CCS Class 2-4 angina not in need of urgent revascularization
AGENT III Trial: 12 week results
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline
seconds
TCT 2004
Mean change in exercise duration from baseline to 12 weeks
p=ns
AGENT III: 12-week results
415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline.
TCT 2004